volitionrx is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats. volitionrx’s development activities are currently centered in belgium with a focus on bringing its revolutionary diagnostic products to market first in europe, then the u.s. and worldwide. you can find more information about volitionrx at our website at www.volitionrx.com, on twitter at www.twitter.com/volitionrx, linkedin at http://www.linkedin.com/company/volitionrx or facebook at www.facebook.com/volitionrx.
Company profile
Ticker
VNRX
Exchange
Website
CEO
Cameron John Reynolds
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
STANDARD CAPITAL CORP
SEC CIK
Corporate docs
Subsidiaries
Singapore Volition Pte. Limited • Belgian Volition SRL • Volition Diagnostics UK Limited • Volition America, Inc. • Volition Veterinary Diagnostics Development LLC. • Volition Germany GmbH • Volition Global Services SRL ...
IRS number
911949078
VNRX stock data
Latest filings (excl ownership)
D
$100.00 k in equity, sold $100.00 k, 1 investor
26 Mar 24
10-K
2023 FY
Annual report
25 Mar 24
8-K
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
25 Mar 24
8-K
Volition appoints Dr Andrew Retter as Chief Medical Officer
19 Mar 24
UPLOAD
Letter from SEC
3 Jan 24
8-K
Other Events
2 Jan 24
CORRESP
Correspondence with SEC
20 Dec 23
UPLOAD
Letter from SEC
15 Dec 23
8-K
VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre
5 Dec 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
Transcripts
VNRX
Earnings call transcript
2023 Q4
26 Mar 24
VNRX
Earnings call transcript
2023 Q3
15 Nov 23
VNRX
Earnings call transcript
2023 Q2
15 Aug 23
VNRX
Earnings call transcript
2023 Q1
11 May 23
VNRX
Earnings call transcript
2022 Q4
16 Mar 23
VNRX
Earnings call transcript
2022 Q3
15 Nov 22
VNRX
Earnings call transcript
2022 Q2
13 Aug 22
VNRX
Earnings call transcript
2022 Q1
12 May 22
VNRX
Earnings call transcript
2021 Q4
31 Mar 22
VNRX
Earnings call transcript
2021 Q3
13 Nov 21
Latest ownership filings
3
Andrew Retter
22 Mar 24
SC 13G/A
Lagoda Investment Management, L.P.
14 Feb 24
SC 13D/A
Reynolds Cameron John
9 Feb 24
4
Gael Forterre
26 Jan 24
4
Gaetan Michel
26 Jan 24
4
Guy Archibald Innes
26 Jan 24
4
Jacob Vincent Micallef
26 Jan 24
4
Jasmine Kway
26 Jan 24
4
Kim Nguyen
26 Jan 24
4
Martin Charles Faulkes
26 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.81 mm | 10.81 mm | 10.81 mm | 10.81 mm | 10.81 mm | 10.81 mm |
Cash burn (monthly) | 2.98 mm | 467.28 k | 2.88 mm | 2.94 mm | 2.81 mm | 2.53 mm |
Cash used (since last report) | 17.82 mm | 2.80 mm | 17.26 mm | 17.58 mm | 16.79 mm | 15.11 mm |
Cash remaining | -7.01 mm | 8.01 mm | -6.45 mm | -6.77 mm | -5.98 mm | -4.30 mm |
Runway (months of cash) | -2.4 | 17.1 | -2.2 | -2.3 | -2.1 | -1.7 |
Institutional ownership, Q2 2023
22.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 35 |
Opened positions | 2 |
Closed positions | 6 |
Increased positions | 8 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 9.00 bn |
Total shares | 18.50 mm |
Total puts | 8.60 k |
Total calls | 87.40 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Eight | 12.05 mm | $36.62 mm |
Lagoda Investment Management | 3.93 mm | $5.46 bn |
BLK Blackrock | 568.03 k | $789.56 mm |
Vanguard | 520.40 k | $723.35 mm |
Geode Capital Management | 465.21 k | $646.65 mm |
MS Morgan Stanley | 218.21 k | $303.31 mm |
Cowen Prime Advisors | 178.74 k | $248.45 mm |
Bridgeway Capital Management | 176.10 k | $244.78 mm |
STT State Street | 123.92 k | $172.25 mm |
NTRS Northern Trust | 70.09 k | $97.43 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Jan 24 | Terig Hughes | Common Stock | Grant | Acquire A | No | No | 0 | 33,150 | 0.00 | 318,890 |
24 Jan 24 | Ann-Louise Batchelor | Common Stock | Grant | Acquire A | No | No | 0 | 22,525 | 0.00 | 74,614 |
24 Jan 24 | Colman Alan | Common Stock | Grant | Acquire A | No | No | 0 | 8,500 | 0.00 | 186,779 |
24 Jan 24 | Reynolds Cameron John | Common Stock | Grant | Acquire A | No | No | 0 | 50,150 | 0.00 | 1,754,668 |
News
Cantor Fitzgerald Reiterates Overweight on VolitionRX, Maintains $2.5 Price Target
27 Mar 24
EF Hutton Maintains Buy on VolitionRX, Maintains $4.5 Price Target
27 Mar 24
VolitionRX Q4 EPS $(0.11), Inline, Sales $243.97K Miss $450.00K Estimate
25 Mar 24
VolitionRx Cash And Cash Equivalents As Of December 31, 2023, Totaled ~$20.7M
25 Mar 24
Earnings Scheduled For March 25, 2024
25 Mar 24
Press releases
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
25 Mar 24
VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update
21 Mar 24
Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan
20 Mar 24
Volition appoints Dr Andrew Retter as Chief Medical Officer
19 Mar 24
Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar
2 Feb 24